ContraFect (CFRXQ) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	CFRX
Entity Registrant Name	CONTRAFECT Corp
Entity Central Index Key	1478069
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,320,728

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$12,354,668	$25,722,453
Marketable securities	10,526,228	1,670,606
Prepaid expenses and other current assets	271,726	368,787
Total current assets	23,152,622	27,761,846
Property and equipment, net	2,013,819	2,148,155
Other assets	143,621	143,621
Total assets	25,310,062	30,053,622
Current liabilities:
Accounts payable	951,327	481,626
Accrued liabilities	1,750,105	2,711,207
Deferred rent	981,104	966,278
Total current liabilities	3,682,536	4,159,111
Warrant liabilities	525,059	313,004
Total liabilities	4,207,595	4,472,115
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value, 25,000,000 shares authorized and none outstanding at March 31, 2015 and December 31, 2014
Common stock, $0.0001 par value, 100,000,000 shares authorized; 20,229,141 and 20,217,263 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	2,022	2,021
Additional paid-in capital	118,458,988	118,038,560
Accumulated other comprehensive loss	-48,333	-627
Accumulated deficit	-97,310,210	-92,458,447
Total stockholders' equity	21,102,467	25,581,507
Total liabilities and stockholders' equity	$25,310,062	$30,053,622

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	20,229,141	20,217,263
Common stock, shares outstanding	20,229,141	20,217,263

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$2,422,106	$2,665,339
General and administrative	2,272,970	2,122,625
Total operating expenses	4,695,076	4,787,964
Loss from operations	-4,695,076	-4,787,964
Other income (expense):
Interest income (expense), net	55,368	-827,995
Refundable state tax credits		328,516
Change in fair value of warrant and embedded derivative liabilities	-212,055	74,631
Total other income (expense)	-156,687	-424,848
Net loss	($4,851,763)	($5,212,812)
Per share information:
Net loss per share of common stock, basic and diluted	($0.24)	($5.15)
Basic and diluted weighted average shares outstanding	20,221,463	1,011,997

Statements_of_Comprehensive_Lo

Statements of Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net loss	($4,851,763)	($5,212,812)
Other comprehensive loss:
Net unrealized loss on available-for-sale securities	-47,706
Comprehensive loss	($4,899,469)	($5,212,812)

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($4,851,763)	($5,212,812)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	134,336	139,628
Stock-based compensation expense	420,029	154,839
Issuance of preferred stock and other costs in exchange for licensed technology		1,000,000
Amortization of debt issuance costs		207,679
Amortization of debt discount		374,527
Change in fair value of warrant and embedded derivative liabilities	212,055	-74,631
Increase in deferred rent	14,826	13,112
Other non-cash items	-28,977
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	97,061	-6,549
(Decrease) increase in accounts payable and accrued liabilities	-491,406	641,472
Net cash used in operating activities	-4,493,839	-2,762,735
Cash flows from investing activities
Purchases of marketable securities	-9,374,346
Proceeds from maturities of marketable securities	500,000
Net cash used in investing activities	-8,874,346
Cash flows from financing activities
Proceeds from issuance of convertible notes		1,155,000
Proceeds from exercise of warrants	400
Net cash provided by financing activities	400	1,155,000
Net decrease in cash and cash equivalents	-13,367,785	-1,607,735
Cash and cash equivalents at beginning of period	25,722,453	4,145,270
Cash and cash equivalents at end of period	$12,354,668	$2,537,535

Organization_and_Description_o

Organization and Description of Business	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Description of Business	1. Organization and Description of Business
	Organization and Business
	ContraFect Corporation (the “Company”) is a clinical-stage biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. The Company intends to address multi-drug resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses. The Company’s most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza.
	The Company has incurred losses from operations since inception as a research and development organization and has relied on its ability to fund its operations through public and private debt and equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future as it enters clinical trials. Transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability and will continue to need to raise additional capital to fund near-term operations. Management intends to fund future operations through additional public or private equity financings, and may seek additional capital through arrangements with strategic partners or from other sources. There can be no assurances that such financing will be available to the Company on satisfactory terms, or at all. In August 2014, the Company completed its initial public offering of 6,000,000 units and closed on the underwriter’s over-allotment option for 880,333 units (the “IPO”), raising total net proceeds of $35.0 million, net of underwriting discount, commissions and offering expenses. The significant increase in common stock outstanding in August 2014 will impact the period to period comparability of the Company’s net loss per share calculations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying financial information as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2014 balance sheet was derived from the Company’s audited financial statements. The Company’s audited financial statements as of and for the year ended December 31, 2014, including all related disclosures and the complete listing of significant accounting policies as described in Note 2 thereof, are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 26, 2015.
	In the opinion of management, the unaudited financial information as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
	Significant Risks and Uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products and the Company’s ability to raise capital. See “Risk Factors” contained elsewhere in this Quarterly Report on Form 10-Q for additional risks and uncertainties.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
	Concentrations of Credit Risk
	Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities and warrant liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The fair value of the Company’s warrant liabilities are based upon unobservable inputs, as described further below.
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurements and Disclosures (ASC 820), establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:
	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	The Company had no liabilities classified as Level 1 or Level 2. The carrying amounts reported in the accompanying financial statements for accounts payable and accrued expenses approximate their respective fair values due to their short-term maturities. The fair value of the warrant and embedded derivative liabilities are discussed in Note 4, “Fair Value Measurements.”
	Share-based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Compensation expense based on the grant date fair value is generally amortized over the requisite service period of the award on a straight-line basis.
	The fair value of options is calculated using the Black-Scholes option pricing model to determine the fair value of stock options on the date of grant based on key assumptions such as stock price, expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on historical data, peer company data and judgment regarding future trends and factors. Prior to being a public company, the Company utilized significant estimates and assumptions in determining the fair value of its common stock.
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net loss per share calculation, stock options and warrant are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive given the Company’s net loss; therefore, basic and diluted net loss per share were the same for all periods presented.
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net loss and changes in unrealized gains and losses on available-for-sale securities.
	Recent Accounting Pronouncements
	In August 2014, the FASB issued a new Accounting Standards Update, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15). ASU 2014-15 provides guidance on management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year of the date the financial statements are issued, and, if such conditions exist, to provide related footnote disclosures. The guidance is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its financial statements and related disclosures.

Marketable_Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities
	Marketable securities at March 31, 2015 and December 31, 2014 consisted of investments in short-term corporate debt securities. Management determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its marketable securities as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities. Marketable securities are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders’ equity (deficit) and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The fair value of these securities is based on quoted prices for identical or similar assets. Realized gains and losses are included in investment income on a specific-identification basis. There were no realized gains or losses on marketable securities for the three months ended March 31, 2015.
	The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period.
	Marketable securities at March 31, 2015 consist of the following:
	Marketable Securities	Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gains		Losses
	Current:
	Corporate debt	$	10,574,561	$	—	$	(48,333	)	$	10,526,228
	Marketable securities at December 31, 2014 consisted of the following:
	Marketable Securities	Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gains		Losses
	Current:
	Corporate debt	$	1,671,233	$	159		$     (786)		$	1,670,606
	At March 31, 2015 and December 31, 2014, the Company held only current investments. Investments classified as current have maturities of less than one year. Investments that would be classified as non-current are those that have maturities of greater than one year and management does not intend to liquidate within the next twelve months.
	At March 31, 2015 and December 31, 2014, the Company held 22 and three debt securities, respectively, that individually and in total were in an immaterial unrealized loss position for less than one year. The aggregate fair value of debt securities in an unrealized loss position at March 31, 2015 and December 31, 2014 was $10,526,228 and $1,222,291, respectively. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of March 31, 2015 and December 31, 2014.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements
	The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
			Fair Value Measurement as of March 31, 2015
			Quoted Prices			Significant			Significant
			in Active			Other Observable			Unobservable
			Markets for			Inputs			Inputs
			Identical Assets			(Level 2)			(Level 3)
			(Level 1)
	Cash equivalents		$	11,942,431		$	—		$	—
	Marketable securities			10,526,228			—			—
	Warrant liability			—			—			525,059
	Total		$	22,468,659		$	—		$	525,059
			Fair Value Measurement as of December 31, 2014
			Quoted Prices			Significant			Significant
			in Active			Other Observable			Unobservable
			Markets for			Inputs			Inputs
			Identical Assets			(Level 2)			(Level 3)
			(Level 1)
	Cash equivalents		$	25,628,918		$	—		$	—
	Marketable securities			1,670,606			—			—
	Warrant liability			—			—			313,004
	Total		$	27,299,524		$	—		$	313,004
	The Company issued a warrant to the underwriter of its IPO, classified it as a liability and considers it as a Level 3 financial instrument (see also Note 8, “Capital Structure”). The warrant will be re-measured at each subsequent reporting period and changes in fair value will be recognized in the statement of operations. The following assumptions were used in a Black-Scholes option-pricing model to determine the fair value of the warrant liability:
			As of			As of
			March 31, 2015			December 31, 2014
	Expected volatility			74.1	%		74.8	%
	Remaining contractual term (in years)			4.42			4.67
	Risk-free interest rate			1.37	%		1.65	%
	Expected dividend yield			—	%		—	%
	The following tables present a reconciliation of the Company’s financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2015 and 2014:
	Warrant liabilities (1)
			Three Months Ended
			March 31,
			2015			2014
	Balance at beginning of period		$	313,004		$	3,088,017
	Issuances of convertible notes			—			254,259
	Increase in fair value (2)			212,055			920,848
	Balance at end of period		$	525,059		$	4,263,124
	Embedded derivatives liabilities (1)
			Three Months Ended
			March 31,
			2015			2014
	Balance at beginning of period		$	—		$	2,680,780
	Issuances of convertible notes			—			258,802
	Decrease in fair value (2)			—			(995,479	)
	Balance at end of period		$	—		$	1,944,103
	-1	Prior to the closing of the Company’s IPO on August 1, 2014, the Company considered its convertible note related warrant liabilities and embedded derivatives liabilities as Level 3 financial instruments. The Company determined the fair value of these liabilities immediately prior to the Company’s IPO and then reclassified the balances to additional paid-in capital on the closing of the IPO.
	-2	The change in the fair values of the warrant and embedded derivatives liabilities are recorded in other expenses in the statement of operations.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses
	Accrued expenses consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued compensation costs	$	851,296	$	1,865,778
	Accrued professional fees		543,094		286,443
	Accrued research and development fees		177,197		202,183
	Accrued licensing fees		—		200,000
	Other		178,518		156,803
		$	1,750,105	$	2,711,207

Senior_Convertible_Notes

Senior Convertible Notes	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Senior Convertible Notes	6. Senior Convertible Notes
	The Company issued approximately $15.0 million in aggregate principal amount of its 8.00% Convertible Notes due May 31, 2015 (the “Convertible Notes”) from June 2013 through June 2014. On August 1, 2014, in conjunction with the closing of the Company’s IPO, the principal amount of the Convertible Notes, and all accrued and unpaid interest thereon, automatically converted into 5,109,988 shares of common stock. Upon the closing of the offering, the Company accelerated the amortization of the remaining debt discount balance to interest expense.

Net_Loss_Per_Share_of_Common_S

Net Loss Per Share of Common Stock	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Share of Common Stock	7. Net Loss Per Share of Common Stock
	Diluted net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company’s net loss. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding.
	The following table sets forth the computation of basic and diluted net loss per share for common stockholders:
		Three Months Ended March 31,
		2015			2014
	Net loss	$	(4,851,763	)	$	(5,212,812	)
	Weighted average shares of common stock outstanding		20,221,463			1,011,997
	Net loss per share of common stock—basic and diluted	$	(0.24	)	$	(5.15	)
	The following potentially dilutive securities outstanding at March 31, 2015 and 2014 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive given the Company’s net loss:
		March 31,
		2015			2014
	Preferred stock		—			4,598,164
	Stock options		3,791,577			2,296,148
	Class A Warrants		6,880,333			—
	Class B Warrants		3,440,066			—
	Warrants (1)		4,256,862			718,322
			18,368,838			7,612,634
	(1) The potential dilutive impact of the Company’s Convertible Notes and related warrants are not included as of March 31, 2014 as the number of shares was not determinable at that time and would also have been anti-dilutive given the Company’s net loss. On the closing of the Company’s IPO on August 1, 2014, the Company determined the total number of shares of the Company’s common stock underlying the warrants held by purchasers of the Convertible Notes to be 3,321,416 at an exercise price of $3.00 per share.

Capital_Structure

Capital Structure	3 Months Ended
	Mar. 31, 2015
Federal Home Loan Banks [Abstract]
Capital Structure	8. Capital Structure
	Common Stock
	As of March 31, 2015, the Company was authorized to issue 100,000,000 shares of common stock at $0.0001 par value per share.
	Initial Public Offering
	On August 1, 2014, the Company closed an initial public offering of its units (the “IPO”). Each unit consisted of one share of common stock, one Class A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B Warrant to purchase one-half share of common stock at an exercise price of $4.00 per full share (the “Units”). The closing of the IPO resulted in the sale of an aggregate of 6,880,333 Units at a public offering price of $6.00 per Unit, less underwriting discounts and commissions and the underwriter’s expenses, including 880,333 Units issued upon the exercise by the underwriters of their option to purchase additional Units at the public offering price to cover over-allotments. The Company received net proceeds from the IPO of $35.0 million, after deducting underwriting discounts, commissions, and expenses payable by the Company. The common stock and accompanying Class A and Class B warrants have been classified to stockholders’ equity (deficit) in the Company’s balance sheet.
	In July 2014, the stockholders approved an amended certificate of incorporation that became effectively immediately upon the closing of the Company’s IPO. The approved certificate increased the number of authorized shares of common stock to 100,000,000 shares.
	Underwriter’s Warrant
	Maxim, the underwriter in the IPO, received a warrant to purchase 3% of the total number of shares of common stock sold in the IPO, including those shares sold upon the exercise of the over-allotment option, for a total of 206,410 shares of common stock underlying the underwriter’s warrant. The warrant is exercisable at an exercise price of $7.50 per share beginning 180 days after the effective date of the Company’s registration statement and expiring on August 27, 2019. The Company classified this warrant as a liability since it did not meet the requirements to be included in equity. The fair value of the warrant will be re-measured at each reporting period and changes in fair value will be recognized in the statement of operations.
	Voting
	The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings.
	Dividends
	The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors. As of March 31, 2015, no dividends have been declared or paid on the Company’s common stock since inception.
	Reserved for Future Issuance
	The Company has reserved for future issuance the following number of shares of common stock as of March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Options to purchase common stock		3,791,577		3,089,327
	Class A Warrants to purchase common stock		6,880,333		6,880,333
	Class B Warrants to purchase common stock		3,440,066		3,440,166
	Warrants to purchase common stock		4,256,862		4,256,862
			18,368,838		17,666,688
	Convertible Preferred Stock
	On August 1, 2014, in conjunction with the closing of the Company’s IPO, all outstanding shares of the Company’s preferred stock, including the in-kind dividend payable, were automatically converted into 6,861,968 shares of its common stock.

Stock_Warrants

Stock Warrants	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Stock Warrants	9. Stock Warrants
	As of March 31, 2015 and December 31, 2014, the Company had warrants outstanding as shown in the table below.
		March 31,		December 31,
		2015		2014
	Warrants to purchase common stock		14,577,261		14,577,361
	Weighted-average exercise price per share	$	4.32	$	4.32
	The following table summarizes information regarding the Company’s warrants outstanding at March 31, 2015:
	Exercise Prices	Shares		Expiry Date
		Underlying
		Outstanding
		Warrants
	£ $3.50		3,656,086	August 31, 2016 – September 1, 2021
	$4.00		3,440,066	October 31, 2015
	$4.80		6,880,333	January 31, 2017
	$5.00 - $9.99		412,434	August 6, 2015 – June 27, 2021
	³ $10.00		188,342	August 31, 2016 – January 5, 2022
			14,577,261

Stock_Option_and_Incentive_Pla

Stock Option and Incentive Plans	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option and Incentive Plans	10. Stock Option and Incentive Plans
	Amended and Restated 2008 Equity Incentive Plan
	In July 2008, the Company adopted the 2008 Equity Incentive Plan (the “Plan”). The Plan allows for the granting of non-qualified stock options, restricted stock, stock appreciation rights and other performance awards to the Company’s employees, members of the board of directors and consultants of the Company.
	Upon the original adoption of the Plan, the number of shares of common stock reserved pursuant to the Plan was 214,285. On December 12, 2011, the Plan was amended to increase the number of shares of common stock available under the Plan to 900,000. On February 24, 2014, the board of directors increased the number of shares of common stock available under the Plan to 1,857,142. On April 29, 2014, the board of directors increased the number of shares of common stock available under the Plan to 2,357,142. The Company expects no further grants to be made under the Plan.
	2014 Omnibus Incentive Plan
	In April 2014, the Company’s board of directors adopted the 2014 Omnibus Incentive Plan (the “2014 Plan”). The 2014 Plan was approved by the Company’s stockholders on July 3, 2014. The 2014 Plan allows for the granting of incentive and non-qualified stock options, restricted stock and stock unit awards, stock appreciation rights and other performance-based awards to the Company’s employees, members of the board of directors and consultants of the Company. On July 28, 2014, the effective date of the 2014 Plan, the number of shares of common stock reserved pursuant to the 2014 Plan was 571,429. The 2014 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ended December 31, 2014 and continuing until the expiration of the 2014 Plan, equal to the lesser of (i) 4% of the outstanding shares of common stock on such date or (ii) an amount determined by the Company’s board of directors. Consistent with the provision for an annual increase, an additional 808,690 shares of common stock have been reserved under the 2014 Plan.
	The Company recognized compensation expense for share-based compensation based on the fair value of the underlying instrument. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. A summary of stock option activity for the three months ended March 31, 2015, is summarized as follows:
		Number of			Weighted			Weighted		Aggregate
		Options			Average			Average Remaining		Intrinsic Value
					Exercise Price			Contractual Life
								(in years)
	Options outstanding at December 31, 2014		3,089,327		$	4.95
	Granted		706,000			4.62
	Exercised		—			—
	Forfeited		(3,750	)		3.5
	Options outstanding at March 31, 2015		3,791,577			4.89			7.71	$	3,727,960
	Vested and exercisable at March 31, 2015		2,390,704			5.15			6.78	$	2,578,203
	Of the option grants outstanding to purchase 3,791,577 shares of common stock, grants to purchase 682,154 shares of common stock were issued and are outstanding outside the Company’s incentive plans.
	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. The weighted average grant date fair value of options granted during the three months ended March 31, 2015 and 2014 was $4.62 and $4.27, respectively. Total compensation expense recognized amounted to $365,729 and $154,839 for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, the total remaining unrecognized compensation cost related to unvested stock options was $2,989,392 which will be recognized over a weighted average period of approximately 2.89 years.
	The following assumptions were used to compute the fair value of stock option grants:
		Three Months Ended March 31,
		2015			2014
	Risk free interest rate		1.62	%		1.87	%
	Expected dividend yield		—			—
	Expected term (in years)		5.97			5.75
	Expected volatility		73.6	%		73.8	%
	Expected volatility—The Company estimated the expected volatility based on an average of the volatility of similar companies with publicly-traded equity securities. The companies were selected based on their enterprise value, risk profiles, position within the industry, and with historical information sufficient to meet the expected term of the associated award.
	Expected term—The Company based expected term on the midpoint of the vesting period and the contractual term of each respective option grant.
	Risk-free interest rate—The Company estimated the risk-free interest rate in reference to yield on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award.
	Expected dividend yield—The Company estimated the expected dividend yield based on consideration of its historical dividend experience and future dividend expectations. The Company has not historically declared or paid dividends to common stockholders. Moreover, it does not intend to pay dividends in the future, but instead expects to retain any earnings to invest in its continued growth.

Retention_Bonus_Plan

Retention Bonus Plan	3 Months Ended
	Mar. 31, 2015
Postemployment Benefits [Abstract]
Retention Bonus Plan	11. Retention Bonus Plan
	On February 24, 2014, the Company adopted the ContraFect Corporation Retention Bonus Plan (the “Retention Plan”). Under the Retention Plan, participants will vest in and become eligible to receive awards equal to a fixed dollar amount (the “Award Amount”), upon the earliest to occur of any of the following events: (i) the IPO; (ii) a Change of Control (as defined in the Retention Plan); (iii) May 31, 2015; and (iv) a participant’s termination of employment due to death or Disability (as defined in the Retention Plan) (each such event, a “Payment Event”). In the event of an IPO or Change of Control, participants who are then employed by the Company shall be eligible to receive a payment in an amount equal to 1.82 times each participant’s Award Amount. For an IPO Payment Event, the Company intends to pay each participant’s Award Amount in shares of common stock, with a lump sum cash payment in respect of any fractional shares. For a Change of Control Payment Event, the Company intends to pay each participant’s Award Amount in the same form of consideration that the holders of common stock receive in the transaction. The Company intends to pay Award Amounts that vest upon an eligible termination or May 31, 2015 in a lump sum cash payment.
	Prior to the Company’s IPO, Award Amounts totaling $532,700 had been granted under the Retention Plan. Upon the closing of the Company’s IPO, the Company recognized a total of $954,754 of expense associated with the vesting of the grants. On September 11, 2014, the Company issued 133,109 shares of its common stock, net of shares withheld for tax obligations, in payment of the retention grants.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent events
	On April 6, 2015, the Company executed a product development agreement with RRD International, LLC (“RRD”), a clinical product development organization, which provides the Company with integrated and expert level strategic, clinical, medical, regulatory and operational management and execution of its CF-301 clinical program. In conjunction with the execution of the agreement, the Company issued 28,445 shares of its common stock to RRD for the initial $150,000 of services provided.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying financial information as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 has been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2014 balance sheet was derived from the Company’s audited financial statements. The Company’s audited financial statements as of and for the year ended December 31, 2014, including all related disclosures and the complete listing of significant accounting policies as described in Note 2 thereof, are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 26, 2015.
	In the opinion of management, the unaudited financial information as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Significant Risks and Uncertainties	Significant Risks and Uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products and the Company’s ability to raise capital. See “Risk Factors” contained elsewhere in this Quarterly Report on Form 10-Q for additional risks and uncertainties.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentrations of Credit Risk	Concentrations of Credit Risk
	Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities and warrant liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The fair value of the Company’s warrant liabilities are based upon unobservable inputs, as described further below.
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurements and Disclosures (ASC 820), establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:
	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	The Company had no liabilities classified as Level 1 or Level 2. The carrying amounts reported in the accompanying financial statements for accounts payable and accrued expenses approximate their respective fair values due to their short-term maturities. The fair value of the warrant and embedded derivative liabilities are discussed in Note 4, “Fair Value Measurements.”
Share-based Compensation	Share-based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Compensation expense based on the grant date fair value is generally amortized over the requisite service period of the award on a straight-line basis.
	The fair value of options is calculated using the Black-Scholes option pricing model to determine the fair value of stock options on the date of grant based on key assumptions such as stock price, expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on historical data, peer company data and judgment regarding future trends and factors. Prior to being a public company, the Company utilized significant estimates and assumptions in determining the fair value of its common stock.
Net Loss Per Share	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net loss per share calculation, stock options and warrant are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive given the Company’s net loss; therefore, basic and diluted net loss per share were the same for all periods presented.
Comprehensive Income (Loss)	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net loss and changes in unrealized gains and losses on available-for-sale securities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the FASB issued a new Accounting Standards Update, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15). ASU 2014-15 provides guidance on management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year of the date the financial statements are issued, and, if such conditions exist, to provide related footnote disclosures. The guidance is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its financial statements and related disclosures.

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Securities	Marketable securities at March 31, 2015 consist of the following:
	Marketable Securities	Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gains		Losses
	Current:
	Corporate debt	$	10,574,561	$	—	$	(48,333	)	$	10,526,228
	Marketable securities at December 31, 2014 consisted of the following:
	Marketable Securities	Amortized		Unrealized		Unrealized			Fair Value
		Cost		Gains		Losses
	Current:
	Corporate debt	$	1,671,233	$	159		$     (786)		$	1,670,606

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Information about Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
			Fair Value Measurement as of March 31, 2015
			Quoted Prices			Significant			Significant
			in Active			Other Observable			Unobservable
			Markets for			Inputs			Inputs
			Identical Assets			(Level 2)			(Level 3)
			(Level 1)
	Cash equivalents		$	11,942,431		$	—		$	—
	Marketable securities			10,526,228			—			—
	Warrant liability			—			—			525,059
	Total		$	22,468,659		$	—		$	525,059
			Fair Value Measurement as of December 31, 2014
			Quoted Prices			Significant			Significant
			in Active			Other Observable			Unobservable
			Markets for			Inputs			Inputs
			Identical Assets			(Level 2)			(Level 3)
			(Level 1)
	Cash equivalents		$	25,628,918		$	—		$	—
	Marketable securities			1,670,606			—			—
	Warrant liability			—			—			313,004
	Total		$	27,299,524		$	—		$	313,004
Assumption Used to Determine Fair Value of Warrant Liability	The following assumptions were used in a Black-Scholes option-pricing model to determine the fair value of the warrant liability:
			As of			As of
			March 31, 2015			December 31, 2014
	Expected volatility			74.1	%		74.8	%
	Remaining contractual term (in years)			4.42			4.67
	Risk-free interest rate			1.37	%		1.65	%
	Expected dividend yield			—	%		—	%
Reconciliation of Company's Financial Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)	The following tables present a reconciliation of the Company’s financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2015 and 2014:
	Warrant liabilities (1)
			Three Months Ended
			March 31,
			2015			2014
	Balance at beginning of period		$	313,004		$	3,088,017
	Issuances of convertible notes			—			254,259
	Increase in fair value (2)			212,055			920,848
	Balance at end of period		$	525,059		$	4,263,124
	Embedded derivatives liabilities (1)
			Three Months Ended
			March 31,
			2015			2014
	Balance at beginning of period		$	—		$	2,680,780
	Issuances of convertible notes			—			258,802
	Decrease in fair value (2)			—			(995,479	)
	Balance at end of period		$	—		$	1,944,103
	-1	Prior to the closing of the Company’s IPO on August 1, 2014, the Company considered its convertible note related warrant liabilities and embedded derivatives liabilities as Level 3 financial instruments. The Company determined the fair value of these liabilities immediately prior to the Company’s IPO and then reclassified the balances to additional paid-in capital on the closing of the IPO.
	-2	The change in the fair values of the warrant and embedded derivatives liabilities are recorded in other expenses in the statement of operations.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued compensation costs	$	851,296	$	1,865,778
	Accrued professional fees		543,094		286,443
	Accrued research and development fees		177,197		202,183
	Accrued licensing fees		—		200,000
	Other		178,518		156,803
		$	1,750,105	$	2,711,207

Net_Loss_Per_Share_of_Common_S1

Net Loss Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share for Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share for common stockholders:
		Three Months Ended March 31,
		2015			2014
	Net loss	$	(4,851,763	)	$	(5,212,812	)
	Weighted average shares of common stock outstanding		20,221,463			1,011,997
	Net loss per share of common stock—basic and diluted	$	(0.24	)	$	(5.15	)
Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities outstanding at March 31, 2015 and 2014 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive given the Company’s net loss:
		March 31,
		2015			2014
	Preferred stock		—			4,598,164
	Stock options		3,791,577			2,296,148
	Class A Warrants		6,880,333			—
	Class B Warrants		3,440,066			—
	Warrants (1)		4,256,862			718,322
			18,368,838			7,612,634
	(1) The potential dilutive impact of the Company’s Convertible Notes and related warrants are not included as of March 31, 2014 as the number of shares was not determinable at that time and would also have been anti-dilutive given the Company’s net loss. On the closing of the Company’s IPO on August 1, 2014, the Company determined the total number of shares of the Company’s common stock underlying the warrants held by purchasers of the Convertible Notes to be 3,321,416 at an exercise price of $3.00 per share.

Capital_Structure_Tables

Capital Structure (Tables)	3 Months Ended
	Mar. 31, 2015
Federal Home Loan Banks [Abstract]
Summary of Common Stock Reserved for Future Issuance	The Company has reserved for future issuance the following number of shares of common stock as of March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Options to purchase common stock		3,791,577		3,089,327
	Class A Warrants to purchase common stock		6,880,333		6,880,333
	Class B Warrants to purchase common stock		3,440,066		3,440,166
	Warrants to purchase common stock		4,256,862		4,256,862
			18,368,838		17,666,688

Stock_Warrants_Tables

Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Schedule of Warrants Outstanding	As of March 31, 2015 and December 31, 2014, the Company had warrants outstanding as shown in the table below.
		March 31,		December 31,
		2015		2014
	Warrants to purchase common stock		14,577,261		14,577,361
	Weighted-average exercise price per share	$	4.32	$	4.32
	The following table summarizes information regarding the Company’s warrants outstanding at March 31, 2015:
	Exercise Prices	Shares		Expiry Date
		Underlying
		Outstanding
		Warrants
	£ $3.50		3,656,086	August 31, 2016 – September 1, 2021
	$4.00		3,440,066	October 31, 2015
	$4.80		6,880,333	January 31, 2017
	$5.00 - $9.99		412,434	August 6, 2015 – June 27, 2021
	³ $10.00		188,342	August 31, 2016 – January 5, 2022
			14,577,261

Stock_Option_and_Incentive_Pla1

Stock Option and Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2015, is summarized as follows:
		Number of			Weighted			Weighted		Aggregate
		Options			Average			Average Remaining		Intrinsic Value
					Exercise Price			Contractual Life
								(in years)
	Options outstanding at December 31, 2014		3,089,327		$	4.95
	Granted		706,000			4.62
	Exercised		—			—
	Forfeited		(3,750	)		3.5
	Options outstanding at March 31, 2015		3,791,577			4.89			7.71	$	3,727,960
	Vested and exercisable at March 31, 2015		2,390,704			5.15			6.78	$	2,578,203
Assumptions to Compute Fair Value of Stock Option Grants	The following assumptions were used to compute the fair value of stock option grants:
		Three Months Ended March 31,
		2015			2014
	Risk free interest rate		1.62	%		1.87	%
	Expected dividend yield		—			—
	Expected term (in years)		5.97			5.75
	Expected volatility		73.6	%		73.8	%

Organization_and_Description_o1

Organization and Description of Business - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Aug. 01, 2014	Aug. 31, 2014
Organization And Description Of Business [Line Items]
Net proceeds from initial public offering	$35	$35
Initial Public Offering [Member]
Organization And Description Of Business [Line Items]
Shares issued		6,000,000
IPO Over-Allotment [Member]
Organization And Description Of Business [Line Items]
Shares issued		880,333

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Maturity period of highly liquid investments	Three months or less
Level 1 [Member]
Summary Of Significant Accounting Policies [Line Items]
Liabilities	0
Level 2 [Member]
Summary Of Significant Accounting Policies [Line Items]
Liabilities	0

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
	Debt_Security	Debt_Security
Marketable Securities [Abstract]
Realized gains or losses on marketable securities	$0
Maturity period classified current investments	Less than one year
Maturity period classified non-current investments	Greater than one year and management does not intend to liquidate within the next twelve months.
Number of debt securities held	22	3
Aggregate fair value of debt securities	$10,526,228	$1,222,291

Marketable_Securities_Schedule

Marketable Securities - Schedule of Marketable Securities (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Marketable Securities [Line Items]
Marketable Securities, Fair Value	$10,526,228	$1,670,606
Corporate Debt [Member]
Marketable Securities [Line Items]
Marketable Securities, Amortized Cost	10,574,561	1,671,233
Marketable Securities, Unrealized Gains		159
Marketable Securities, Unrealized Losses	-48,333	-786
Marketable Securities, Fair Value	$10,526,228	$1,670,606

Fair_Value_Measurements_Inform

Fair Value Measurements - Information about Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Marketable securities	$10,526,228	$1,670,606
Warrant liability	525,059	313,004
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Cash equivalents	11,942,431	25,628,918
Marketable securities	10,526,228	1,670,606
Total	22,468,659	27,299,524
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Warrant liability	525,059	313,004
Total	$525,059	$313,004

Fair_Value_Measurements_Assump

Fair Value Measurements - Assumption Used to Determine Fair Value of Warrant Liability (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Expected volatility	74.10%	74.80%
Remaining contractual term (in years)	4 years 5 months 1 day	4 years 8 months 1 day
Risk-free interest rate	1.37%	1.65%
Expected dividend yield	0.00%	0.00%

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of Company's Financial Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$313,004	$3,088,017
Issuances of convertible notes		254,259
Increase (Decrease) in fair value	212,055	920,848
Balance at end of period	525,059	4,263,124
Embedded Derivatives Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period		2,680,780
Issuances of convertible notes		258,802
Increase (Decrease) in fair value		-995,479
Balance at end of period		$1,944,103

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued compensation costs	$851,296	$1,865,778
Accrued professional fees	543,094	286,443
Accrued research and development fees	177,197	202,183
Accrued licensing fees		200,000
Other	178,518	156,803
Accrued expenses and other current liabilities	$1,750,105	$2,711,207

Senior_Convertible_Notes_Addit

Senior Convertible Notes - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Aug. 01, 2014
Debt Instrument [Line Items]
IPO, closing date	1-Aug-14
8.00% Convertible Notes due May 31, 2015 [Member]
Debt Instrument [Line Items]
Convertible Notes, principal amount	15
Convertible Notes, interest rate	8.00%
Convertible Notes, due date	31-May-15
Initial Public Offering [Member]
Debt Instrument [Line Items]
Conversion of Convertible Notes together with accrued and unpaid interest into common stock, shares		5,109,988

Net_Loss_Per_Share_of_Common_S2

Net Loss Per Share of Common Stock - Schedule of Computation of Basic and Diluted Net Loss Per Share for Common Stockholders (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($4,851,763)	($5,212,812)
Weighted average shares of common stock outstanding	20,221,463	1,011,997
Net loss per share of common stock-basic and diluted	($0.24)	($5.15)

Net_Loss_Per_Share_of_Common_S3

Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares	18,368,838	7,612,634
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares		4,598,164
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares	3,791,577	2,296,148
Class A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares	6,880,333
Class B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares	3,440,066
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially antidilutive securities outstanding excluded from the computation of diluted weighted average shares	4,256,862	718,322

Net_Loss_Per_Share_of_Common_S4

Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Parenthetical) (Detail) (USD $)	Mar. 31, 2015	Aug. 01, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock held by Convertible Notes holders, exercise price	$7.50
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock held by Convertible Notes holders		3,321,416
Common stock held by Convertible Notes holders, exercise price		$3

Capital_Structure_Additional_I

Capital Structure - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended
	Mar. 31, 2015	Aug. 01, 2014	Aug. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Jul. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized	100,000,000			100,000,000	100,000,000	100,000,000
Common stock, par value	$0.00			$0.00	$0.00
IPO, closing date				1-Aug-14
Initial public offering, units description				Each unit consisted of one share of common stock, one Class A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B Warrant to purchase one-half share of common stock at an exercise price of $4.00 per full share (the "Units").
Warrant exercise price per share	$7.50			$7.50
Common stock units issued upon exercise of option by underwriters				206,410
Net proceeds from initial public offering		$35,000,000	$35,000,000
Class of warrant purchase percentage	3.00%			3.00%
Warrant expiration date				27-Aug-19
Warrant exercisable period				180 days
Common stock, voting rights				The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings.
Dividends declared or paid	$0
Number of shares issued on conversion of preferred stock including in-kind dividend payable into common stock		6,861,968
Initial Public Offering [Member]
Class of Stock [Line Items]
Common stock units sold by initial public offering		6,880,333
Public offering price, per unit		$6
Common stock units issued upon exercise of option by underwriters		880,333
Common Class A [Member] | Initial Public Offering [Member]
Class of Stock [Line Items]
Warrant exercise price per share		$4.80
Common Class B [Member] | Initial Public Offering [Member]
Class of Stock [Line Items]
Warrant exercise price per share		$4

Capital_Structure_Summary_of_C

Capital Structure - Summary of Common Stock Reserved for Future Issuance (Detail)	Mar. 31, 2015	Dec. 31, 2014	Apr. 29, 2014	Feb. 24, 2014
Class of Stock [Line Items]
Total Common Stock reserved for future issuance	18,368,838	17,666,688	2,357,142	1,857,142
Stock Options [Member]
Class of Stock [Line Items]
Total Common Stock reserved for future issuance	3,791,577	3,089,327
Class A Warrants [Member]
Class of Stock [Line Items]
Total Common Stock reserved for future issuance	6,880,333	6,880,333
Class B Warrants [Member]
Class of Stock [Line Items]
Total Common Stock reserved for future issuance	3,440,066	3,440,166
Warrants [Member]
Class of Stock [Line Items]
Total Common Stock reserved for future issuance	4,256,862	4,256,862

Stock_Warrants_Schedule_of_War

Stock Warrants - Schedule of Warrants Outstanding (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Warrants to purchase common stock	$14,577,261	$14,577,361
Weighted-average exercise price per share	$4.32	$4.32
Exercise Prices	$7.50
Shares Underlying Outstanding Warrants	14,577,261
Expiry Date	27-Aug-19
Exercise Price Less Than or Equal to $3.50 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$3.50
Shares Underlying Outstanding Warrants	3,656,086
Expiry Start Date	31-Aug-16
Expiry End Date	1-Sep-21
Exercise Price $4.00 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$4
Shares Underlying Outstanding Warrants	3,440,066
Expiry Date	31-Oct-15
Exercise Price $4.80 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$4.80
Shares Underlying Outstanding Warrants	6,880,333
Expiry Date	31-Jan-17
Exercise Price $5.00 - $9.99 [Member]
Class of Warrant or Right [Line Items]
Shares Underlying Outstanding Warrants	412,434
Expiry Start Date	6-Aug-15
Expiry End Date	27-Jun-21
Exercise Price Greater Than or Equal to $10.00 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$10
Shares Underlying Outstanding Warrants	188,342
Expiry Start Date	31-Aug-16
Expiry End Date	5-Jan-22
Minimum [Member] | Exercise Price $5.00 - $9.99 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$5
Maximum [Member] | Exercise Price $5.00 - $9.99 [Member]
Class of Warrant or Right [Line Items]
Exercise Prices	$9.99

Stock_Option_and_Incentive_Pla2

Stock Option and Incentive Plans - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 28, 2014	Dec. 31, 2014	Apr. 29, 2014	Feb. 24, 2014	Jul. 31, 2008	Dec. 12, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved pursuant to the plan	18,368,838			17,666,688	2,357,142	1,857,142
Number of common stock shares outstanding	3,791,577			3,089,327
Number of common stock available for grant	682,154
Weighted average period of unvested stock options	2 years 10 months 21 days
Weighted average grant date fair value of options	$4.62	$4.27
Compensation expense recognized	$365,729	$154,839
Unrecognized compensation cost related to unvested stock options	$2,989,392
2014 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved pursuant to the plan			571,429
Number of additional shares increases of common stock reserved pursuant to the plan	808,690
2014 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase of plan, percentage of common stock shares outstanding			4.00%
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved pursuant to the plan							214,285
Amended Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved pursuant to the plan								900,000

Stock_Option_and_Incentive_Pla3

Stock Option and Incentive Plans - Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Options outstanding, Beginning balance	3,089,327
Number of Options, Granted	706,000
Number of Options, Exercised	0
Number of Options, Forfeited	-3,750
Number of Options, Options outstanding, Ending balance	3,791,577
Number of Options, Vested and exercisable, Ending Balance	2,390,704
Weighted Average Exercise Price, Options outstanding, Beginning balance	$4.95
Weighted Average Exercise Price, Granted	$4.62
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Forfeited	$3.50
Weighted Average Exercise Price, Options outstanding, Ending balance	$4.89
Weighted Average Exercise Price, Vested and exercisable, Ending balance	$5.15
Weighted Average Remaining Contractual Life (in years), Options outstanding	7 years 8 months 16 days
Weighted Average Remaining Contractual Life (in years), Vested and exercisable	6 years 9 months 11 days
Aggregate Intrinsic value, Options outstanding	$3,727,960
Aggregate Intrinsic value, Vested and exercisable	$2,578,203

Stock_Option_and_Incentive_Pla4

Stock Option and Incentive Plans - Assumptions to Compute Fair Value of Stock Option Grants (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk free interest rate	1.62%	1.87%
Expected dividend yield	$0	$0
Expected term (in years)	5 years 11 months 19 days	5 years 9 months
Expected volatility	73.60%	73.80%

Retention_Bonus_Plan_Additiona

Retention Bonus Plan - Additional Information (Detail) (Retention Plan [Member], USD $)	0 Months Ended	3 Months Ended
	Sep. 11, 2014	Mar. 31, 2015
Retention Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Retention Bonus Plan, description		Under the Retention Plan, participants will vest in and become eligible to receive awards equal to a fixed dollar amount (the bAward Amountb), upon the earliest to occur of any of the following events: (i) the IPO; (ii) a Change of Control (as defined in the Retention Plan); (iii) May 31, 2015; and (iv) a participantbs termination of employment due to death or Disability (as defined in the Retention Plan) (each such event, a bPayment Eventb). In the event of an IPO or Change of Control, participants who are then employed by the Company shall be eligible to receive shares of common stock in an amount equal to 1.82 times each participantbs Award Amount.
Award Amounts granted under retention plan		$532,700
Expense associated with the vesting of the grants		$954,754
Common stock issued in payment of the retention grants	133,109

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (RRD International, LLC [Member], Subsequent Event [Member], Product Development Agreement [Member], USD $)	0 Months Ended
	Apr. 06, 2015
RRD International, LLC [Member] | Subsequent Event [Member] | Product Development Agreement [Member]
Subsequent Event [Line Items]
Common stock issued for services, shares	28,445
Common stock issued for services, value	$150,000